Articles tagged "Sirolimus (SLR)"

2022 American Transplant Congress
Sirolimus Regimens After Kidney Transplantation: Role of Pre-Transplant Risk Factors in Modifying the Risk of Mortality in Adult Recipients
A. Santos¹, H. Ibrahim¹, M. A. Leghrouz¹, X. Wen²
¹University of Florida, Gainesville, FL, ²University of Rhode Island, Kinston, RI
*Purpose: We aimed to investigate the role of risk factors in modifying the association of sirolimus with mortality in kidney transplant (KT) recipients (KTRs).*Methods: Using…
2022 American Transplant Congress
Sting but Not Mtor Signaling Regulates Exogenous Mitochondrion-Induced Endothelial Cell Mitophagy
H. Xu, L. Wang, A. D. Kirk, H. Xu
Duke University School of Medicine, Durham, NC
*Purpose: We have previously demonstrated activation and increasing mitophagy of human endothelial cells (ECs) following exogenous mitochondrion-stimulation. The objectives of this study were to evaluate…
2022 American Transplant Congress
Sirolimus Use Is Associated With An Improved Immune Response To Covid-19 Vaccination In Kidney Transplant Recipients
G. B. Perkins¹, M. Tunbridge², T. Salehi², C. Chai¹, C. M. Hope¹, P. Garcia-Valtanen¹, J. J. Singer³, P. R. Hurtado², S. C. Barry¹, B. Grubor-Bauk¹, P. Hissaria², S. J. Chadban³, P. Coates¹
¹University of Adelaide, Adelaide, Australia, ²Royal Adelaide Hospital, Adelaide, Australia, ³Royal Prince Alfred Hospital, Sydney, Australia
*Purpose: Kidney transplant recipients (KTRs) are highly vulnerable to severe COVID-19, however are poorly protected by vaccination. Additional vaccine doses have achieved limited improvements in…
2022 American Transplant Congress
Impact of Early versus Late Initiation of Sirolimus Regimens on Mortality After Kidney Transplantation: Age-Stratified Analyses of Adult Recipients
A. Santos¹, H. Ibrahim¹, M. A. Leghrouz¹, X. Wen²
¹University of Florida, Gainesville, FL, ²University of Rhode Island, Kingston, FL
*Purpose: Observational and meta-analytic studies have associated sirolimus with an increased risk of mortality in kidney transplant (KT) recipients (KTRs). We aimed to examine the…
2022 American Transplant Congress
Long-Term Effects of Conversion from Calcineurin Inhibitors to Sirolimus for the Recipients with Low Immunological Risk in Renal Allograft
Q. Wu, J. Chen, D. Cheng, X. Ni, X. Li, K. Xie, W. Jiqiu
National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University Jinling School of Medicine, Nanjing, China
*Purpose: To observe the long-term effects and prognosis of conversion from calcineurin inhibitors (CNIs) to sirolimus in biopsy-proven low immunological risk renal transplant recipients (RTRs).*Methods:…
2022 American Transplant Congress
A Prospective Randomised, Controlled Trial Switching Sirolimus For Mycophenolate To Enhance Immunological Responses To Third Dose Covid-19 Vaccination In Kidney Transplant Recipients With Poor Baseline Humoral Immunity
M. J. Tunbridge¹, G. Perkins², T. Salehi¹, B. Grubor-Bauk³, B. Sim¹, T. Ying⁴, J. J. Singer⁵, S. C. Barry⁶, P. Hissaria⁷, S. Chadban⁸, P. T. Coates¹
¹Central and Northern Adelaide Renal and Transplant Services, Royal Adelaide Hospital, Adelaide, Australia, ²School of Biological Sciences, University of Adelaide, Adelaide, Australia, ³Basil Hetzel Institute, University of Adelaide, Adelaide, Australia, ⁴University of Sydney, Lilyfield, Ne, Australia, ⁵Kidney Node Laboratory, Charles Perkins Centre, The University of Sydney, The University of Sydney, Australia, ⁶School of Medical Sciences, University of Adelaide, Adelaide, Australia, ⁷Department of Immunology, Royal Adelaide Hospital, Adelaide, Australia, ⁸Department of Nephrology, Royal Prince Alfred Hospital, Sydney, Australia
*Purpose: Kidney transplant recipients (KTR) have inadequate responses to 2-dose COVID vaccination schedules and are at increased risk of severe COVID-19. Formation of T cell…
2021 American Transplant Congress
Associations of Mammalian Target of Rapamycin Inhibitors with Post-Transplant Malignancies and All-Cause Mortality: Cause-Specific Competing Risks and Composite Outcomes Analyses
A. H. Santos¹, E. Bueno¹, M. A. Leghrouz¹, W. Xuerong²
¹University of Florida, Gainesville, FL, ²University of Rhode Island, Kingston, RI
*Purpose: We investigated the outcomes of malignancies and mortality associated with mammalian target of rapamycin inhibitor (MTORI) regimens in adult kidney transplant (KT) recipients (KTRs).*Methods:…
2021 American Transplant Congress
COVID-19 in Hospitalized Kidney Transplant Recipients: Clinical Course, Prognostic Factors and Differences Between First and Second Waves
N. Macías, M. Rodríguez Ferrero, A. Acosta, J. Carbayo, Á. González Rojas, A. Muñoz de Morales, A. García Prieto, M. Goicoechea
Nephrology, Hospital Gregorio Marañón, Madrid, Spain
*Purpose: The aim was to describe the clinical course and management of SARS-CoV-2 infection in kidney transplant recipients (KTR) hospitalized with COVID-19, identify risk factors…
2021 American Transplant Congress
Kidney Transplant Outcomes Stratified by Race with a Calcineurin and Steroid Free Regimen
R. E. Scalzo, M. T. Harris, J. D. Morris, J. S. Byrns
Pharmacy, Duke University Medical Center, Durham, NC
*Purpose: This study aimed to describe the outcomes, stratified by race, associated with belatacept and sirolimus immunosuppression after alemtuzumab induction.*Methods: This was a retrospective, single-center…
2021 American Transplant Congress
Evaluation of the Conversion from Tacrolimus to Sirolimus in Liver Transplant Recipients
H. Bakhtiari¹, S. Todd², H. Snyder², D. Lo², M. Flynn²
¹Mercer University College of Pharmacy, Atlanta, GA, ²Emory University Hospital, Atlanta, GA
*Purpose: The purpose of this study was to compare outcomes in liver transplant patients maintained on standard calcineurin inhibitor (CNI) therapy with tacrolimus versus those…

1
2
3
…
6
Next Page »